← Back to Clinical Trials
Recruiting NCT05653011
NCT05653011 Predictors of Prognosis in IBD Patients
◆ AI Clinical Summary
Plain-language summary for patients
| NCT ID | NCT05653011 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seoul National University Bundang Hospital |
| Condition | Inflammatory Bowel Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2013-03-11 |
| Primary Completion | 2026-10-31 |
Trial Parameters
Condition Inflammatory Bowel Diseases
Sponsor Seoul National University Bundang Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 100
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2013-03-11
Completion 2026-10-31
All Conditions
Interventions
Endoscopic biopsy
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
A study of clinical characteristics and potential prognostic factors in inflammatory bowel disease
Eligibility Criteria
Inclusion Criteria: * control group: Patients who do not have colitis, cancer, and advanced polyp (the number of polyps ≥ 3, the size of polyps ≥ 1cm, high-grade adenoma, villous adenoma) * TNF-α inhibitor-naive IBD group: IBD patients who do not have a history of TNF-α inhibitor treatment * TNF-α inhibitor-treated IBD group: IBD patients who are treated with TNF-α inhibitor Exclusion Criteria: * Age under 18 years * Patients who were treated with antibiotics or probiotics within the last 3 months
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology